Patent Application Sample Contracts

Share Cite Term
Link

Embed (HTML)
Xtera Communications, Inc. – Grant of Security Interest Patents (October 5th, 2015)

THIS GRANT OF SECURITY INTEREST, dated as of May 10, 2011, is executed by XTERA COMMUNICATIONS, INC., a Delaware corporation with an address of 500 W. Bethany Drive, Suite 100 Allen, Texas 75013 (Debtor), in favor of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an address of 312 Farmington Avenue, Farmington, Connecticut 06032 (Secured Party).

REGENXBIO Inc. – Confidential Treatment Requested (August 17th, 2015)

Please find attached an amended Exhibit A Patents and Patent Applications in Patent Rights for the License Agreement between the Trustees of the University of Pennsylvania and ReGenX, LLC with an Effective Date of February 24, 2009 (the Agreement). The amendment removes Penn docket #K1774 from Exhibit A in its entirety. With the exception of this single change, all other provisions of the Agreement remain in full force and effect.

MyDx, Inc. – Assignment of Provisional Patent Application (May 5th, 2015)

WHEREAS, CDx, Inc. (hereinafter "ASSIGNEE"), a corporation of the state of Delaware, having a place of business at 4225 Executive Square Suite 600, La Jolla, CA 92037, desires to acquire all of the ASSIGNOR'S interest in the Invention;

Assembly Biosciences February 2015 1 Forward - Looking Statements This Presentation Contains Forward - Looking Statements Regarding Future Events. Forward - Looking Statements Involve Known and Unknown Risks That Could Cause Actual Results to Differ Materially From Expected Results. These Risks and Uncertainties Include, Among Others: Risks Related to the Scientific Bases, Costs, Timing, Regulatory Review and Results of Our Studies and Clinical Trials; Our Ability to Obtain FDA and Other Regulatory Approval of Our Product Candidates; Our Anticipated Capital Expenditures, Our Estimates Regardin (February 24th, 2015)
ZERO GRAVITY SOLUTIONS, INC. Assignment as a Below Named Inventor or Joint Inventor of an Invention or Improvement Entitled; BIOAVAILABLE MINERALS FOR PLANT HEALTH U, 5, Provisional Patent Application No. 61/928,233; Filed May 29, 2013 Attorney Docket No. 3081198 U803 (December 29th, 2014)

WHEREAS, the ZERO GRAVITY SOLUTIONS, INC., having its principal office and place of business at 190 N.W. Spanish River Blvd., Suite 101, Boca Raton, Florida 33431, is desirous of obtaining the entire right, title and interest in, to and under the said invention and the said application in the United States of America, and in any and all countries foreign thereto;

Bio-Matrix Scientific Group – Assignment of Invention and Patent Application (December 29th, 2014)

Whereas I, Christine Ichim, a citizen of the Canada residing in Spring Valley, CA herein referred to as ASSIGNOR, have invented new and useful innovations described in "TREATMENT OF MYELODYSPLASTIC SYNDROME BY INHIBITION OF NR2F6", the specification of which was filed on December 16, 2014 as U.S. Non-Provisional Patent Application No 14/572,574, herein referred to as the Invention

Bio-Matrix Scientific Group – Assignment of Invention and Patent Application (December 29th, 2014)

Whereas, I, Christine Ichim ("ASSIGNOR"), a natural person and residing at 12685 Campo Road, Spring Valley CA 91978 desire to assign any and all ownership interest in the inventions described in U.S. Patent Application Serial No. 13/652,395, filed on October 15th, 2012, "Modulation of NR2F6 and methods and uses thereof" known as the "Invention".

Bio-Matrix Scientific Group – Assignment of Invention and Patent Application (December 29th, 2014)

Whereas I, Christine Ichim, a citizen of the Canada residing in Spring Valley, CA herein referred to as ASSIGNOR, have invented new and useful innovations described in METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY INHIBITION OF NR2F6, the specification of which was filed on December 15, 2014 as U.S. Non-Provisional Patent Application No 14/571,262, herein referred to as the Invention

Regen BioPharma Inc – Assignment of Invention and Patent Application (December 18th, 2014)

Whereas I, Christine Ichim, a citizen of the Canada residing in Spring Valley, CA herein referred to as ASSIGNOR, have invented new and useful innovations described in METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY INHIBITION OF NR2F6, the specification of which was filed on December 15, 2014 as U.S. Non-Provisional Patent Application No 14/571,262, herein referred to as the Invention

Regen BioPharma Inc – Assignment of Invention and Patent Application (December 18th, 2014)

Whereas I, Christine Ichim, a citizen of the Canada residing in Spring Valley, CA herein referred to as ASSIGNOR, have invented new and useful innovations described in "TREATMENT OF MYELODYSPLASTIC SYNDROME BY INHIBITION OF NR2F6", the specification of which was filed on December 16, 2014 as U.S. Non-Provisional Patent Application No 14/572,574, herein referred to as the Invention

Regen BioPharma Inc – Assignment of Invention and Patent Application (November 25th, 2014)

Whereas, I, Christine Ichim ("ASSIGNOR"), a natural person and residing at 12685 Campo Road, Spring Valley CA 91978 desire to assign any and all ownership interest in the inventions described in U.S. Patent Application Serial No. 13/652,395, filed on October 15th, 2012, "Modulation of NR2F6 and methods and uses thereof" known as the "Invention".

Amendment No. 1 to Exclusive License Agreement (November 17th, 2014)

This Amendment No. 1 to Exclusive License Agreement (the Amendment No. 1), effective as of September 8, 2014 (the Effective Date), is made by and between Memorial Sloan-Kettering Cancer Center, a New York corporation with principal offices at 1275 York Avenue, New York, New York 10065 (MSKCC), and Juno Therapeutics, Inc., a Delaware corporation having a principal place of business at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98109 (Licensee).

[Proteon Therapeutics Letterhead] January 12, 2009 1010 W. 69th Terr. Kansas City, Missouri 64113 International Patent Application No. PCT/US00/26237 Dear Nick: (September 16th, 2014)

This letter confirms that by accepting your December 30, 2002 assignment of rights to the inventions disclosed in the above-referenced patent applications (the Invention), Proteon Therapeutics, LLC (i) agreed to comply with the terms of the Assignment of Rights/License Agreement between Nicholas Franano and the Johns Hopkins University dated March 25, 2002 (the JHU Agreement) and (ii) assumed your obligations arising from the JHU Agreement (the Franano Obligations), including the obligation to honor the provisions imposed by the federal government sponsor of the research underlying the Invention (the Bayh-Dole Obligations).

[Proteon Therapeutics Letterhead] January 12, 2009 1010 W. 69th Terr. Kansas City, Missouri 64113 International Patent Application No. PCT/US00/26237 Dear Nick: (August 6th, 2014)

This letter confirms that by accepting your December 30, 2002 assignment of rights to the inventions disclosed in the above-referenced patent applications (the Invention), Proteon Therapeutics, LLC (i) agreed to comply with the terms of the Assignment of Rights/License Agreement between Nicholas Franano and the Johns Hopkins University dated March 25, 2002 (the JHU Agreement) and (ii) assumed your obligations arising from the JHU Agreement (the Franano Obligations), including the obligation to honor the provisions imposed by the federal government sponsor of the research underlying the Invention (the Bayh-Dole Obligations).

Safety Quick Lighting & Fans Corp. – QUICK CONNECT ASSEMBLY, IN Patent Application No. 2390/Kolnp/2007 (August 1st, 2014)

NOW THEREFORE be it known to all whom it may concern, that in and for a consideration of Rupees Ten/US $ One in hand paid to me/us receipt whereof is hereby acknowledged 1/We have assigned, transferred and set over and by these presents do assign, transfer and set over unto the said (4)

Helius Medical Technologies, Inc. – Second Amended and Restated Patent Sub-License OF and Provisional Patent Application 61/019,061 (July 14th, 2014)

This Second Amended and Restated Patent Sub-License ("Agreement"), entered into effective as of this 6th day of June, 2014, by and between Advanced NeuroRehabilitation, LLC, a Wisconsin Limited Liability Company. ("ANR"), with offices at 510 Charmany Drive, Suite 175F, Madison, Wisconsin, 53719, and NeuroHabilitation Corporation ("NHC"), a Delaware Corporation (collectively, ANR and NHC are sometimes referred to as the "Parties").

Helius Medical Technologies, Inc. – Amended and Restated Patent Sub-License OF and Provisional Patent Application 61/019,061 (July 14th, 2014)

WHEREAS, ANR holds a license of certain Patent Rights (hereinafter defined) pursuant to a valid License Agreement (the "Master License") dated June 29, 2011 with Yuri P. Danilov, Mitchell E. Tyler, and Kurt

January 25, 2006 (January 24th, 2014)

Isis Pharmaceuticals, Inc. (Isis) and Achaogen, Inc. (Achaogen) are parties to a certain License Agreement of even date herewith (the Agreement) under which Isis has licensed to Achaogen certain intellectual property relating to aminoglycosides and aminoglycoside analogs, including without limitation U.S Patent Application [***] (the Application), all as further specified in the Agreement.

Spherix Acquires Over 100 Patents and Patent Applications Portfolio From Rockstar Consortium (January 6th, 2014)

TYSONS CORNER, Va., Jan. 6, 2014 /PRNewswire/ -- Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, announced that it has entered into a series of agreements with Rockstar Consortium (US) LP in which Spherix Incorporated acquired over 100 patents and patent applications. The newly acquired patents cover among other things, numerous aspects of access, switching, routing, optical and voice communication network devices.

December 18, 2012 (April 29th, 2013)

This letter agreement (this Letter) refers to the Technology Transfer Agreement dated December 18, 2012 (the TTA), between Regado Biosciences, Inc., a Delaware corporation (Regado) and Domain Russia Investments Limited, an English Limited Company (DRI), pursuant to which Regado has assigned certain Assigned IP and licensed certain Licensed IP to DRI in the Territory.

Assignment (April 2nd, 2013)

THIS ASSIGNMENT, effective this 5th day of July, 2010 between Glenn S. Foley, having his principal place of residence at 335 Gorrell St. Greensboro, NC USA "(hereinafter referred to as "the Assignor(s)") and Medical Device International Limited having its principal place at Unit 1001 Fourseas Building, 208-210 Nathan Road, Jordan Kowloon, Hong Kong. (hereinafter referred to as "the Assignee(s)");

Assignment (April 2nd, 2013)

THIS ASSIGNMENT, effective this 3rd day of August, 2010 between Medical Device International Limited having its principal place at Unit 1001 Fourseas Building, 208-212 Nathan Road, Jordan Kowloon, Hong Kong "(hereinafter referred to as "the Assignor(s)") and Life Care Medical Devices Limited having its principal place at Unit 2508A, Bank of America Tower, Central Hong Kong (hereinafter referred to as "the Assignee(s)");

Elite Data Services, Inc. – Confidential Summary of Terms and Conditions for License and Assignment of Certain Rights Including a Provisional Patent Application (October 11th, 2012)

This confidential summary of terms and conditions of license and assignment of certain rights, including a provisional patent application (the "Term Sheet") is entered into this 10th day of October 2012, by and between the parties referenced hereinbelow.

"Affiliate(s)" Means Any Business Entity That Controls, Is Controlled By, or Is Under Common Control With Licensee. Control Means the Direct or Indirect Ownership of at Least Fifty Percent (50%). "Improvement" Shall Mean Any Invention Made by Dr. Charles Dinarello, and Dr. Soohyun Kim ("Inventors") That (I) Is a Modification of the Inventions Claimed in or Covered by the Patent Rights and the Practice of Which Would Infringe the Patent Rights in the Absence of a License, and (Ii) Is Assigned to the University (As Either a Sole or Co-Owner) and Is Not Otherwise Subject to Any Prior Legal or Con (October 2nd, 2012)

The exclusive license granted by this Agreement shall immediately terminate upon Licensee's dissolution, liquidation, insolvency, or bankruptcy. The exclusive license shall NOT pass to a trustee in bankruptcy or be held as an asset of said bankrupt.

Supplementary Agreement to the Share Purchase Agreement (January 11th, 2012)
Patent Collateral Assignment and Security Agreement (January 9th, 2012)

THIS PATENT COLLATERAL ASSIGNMENT AND SECURITY AGREEMENT (Agreement), dated ________ __, 2012, is by and between MMAX Media, Inc., a Nevada corporation, with its chief executive office at 511 NE 3rd Avenue, Suite 100, Fort Lauderdale, Fl 33301 (Debtor) in favor of ________________________, _______________, whose address is ________________________________________________ (collectively the Secured Party).

Second Amendment to License Agreement Between Lankenau Institute for Medical Research and Newlink Genetics Corporation Dated July 7, 2005 (December 21st, 2010)

This Second Amendment to the License Agreement (Second Amendment) between Lankenau Institute for Medical Research (LIMR) and NewLink Genetics Corporation (NewLink or Company) is made on this 11th day of September, 2007 (Effective Date).

OxySure Systems Inc – Attorney Docket No Patent Application Ross 2864000 (October 5th, 2010)

The invention relates generally to oxygen generation and, more particularly, to robust oxygen generation from a solid or liquid.

Assignment of Technologies and Patent Applications From Michael Cohen to Proteonomix, Inc. (January 28th, 2010)

This Assignment Agreement (the Agreement) is made this 1st day of July, 2009, by and between Michael Cohen, residing at 7 Stanford Court, West Orange, New Jersey 07052 (the Assignor); Proteonomix, Inc., a Delaware corporation (Proteonomix) with offices at 187 Mill Lane, Mountainside, New Jersey 07092 (together, the Parties).

Patent Application # (January 19th, 2010)
Novacea – For Second U.S. Patent Application Covering Intermezzo(r) (December 15th, 2009)

Point Richmond, CA, December 14, 2009 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo(r) (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire no earlier than February 2025.

Assignment of Technologies and Patent Applications From Michael Cohen to Proteonomix, Inc. (October 20th, 2009)

This Assignment Agreement (the Agreement) is made this 1st day of July, 2009, by and between Michael Cohen, residing at 7 Stanford Court, West Orange, New Jersey 07052 (the Assignor); Proteonomix, Inc., a Delaware corporation (Proteonomix) with offices at 187 Mill Lane, Mountainside, New Jersey 07092 (together, the Parties).

Assignment of Technologies and Patent Applications (August 4th, 2009)

This Assignment Agreement (the Agreement) is made this 1st day of July, 2009, by and among Michael Cohen, residing at 7 Stanford Court, West Orange, New Jersey 07052 (MC); Jacob Cohen, residing at 25 Brook Place West Orange, New Jersey 07052 (JC)(herein individually an Assignor and collectively the Assignors); Proteonomix, Inc., a Delaware corporation (Proteonomix) and its subsidiary, Proteoderm, Inc. a New York corporation (the Subsidiary), both with offices at 187 Mill Lane, Mountainside, New Jersey 07092 (together, the Parties), entered into this 1st day of July, 2009.

Clean Power Technologies Inc. – Assignment (Non-Provisional Patent Application) (April 10th, 2009)

for which an International Patent Application has been filed on 25 September 2006 under International Patent Application No. PCT/GB2007/003644;

Sino Green Land Corp – (English Translation) TRANSFER AGREEMENT OF PATENT APPLICATION RIGHT (January 21st, 2009)

Based on the voluntary principle, Party A hereby transfers to Party B the patent application right to the invention with the name of Method and Equipment for Cleaning, Sterilizing and Retaining Freshness of the Fruits and Vegetables (Patent Application Number: CN200510088865).